Thèses sur le sujet « Interferoni »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les 50 meilleures thèses pour votre recherche sur le sujet « Interferoni ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Parcourez les thèses sur diverses disciplines et organisez correctement votre bibliographie.
DETTORI, BEATRICE. « Effetti immunoregolatori degli interferoni di prima classe sull’attivita’ delle cellule CD4+CD25- t helper e delle cellule CD4+CD25+ Treg ». Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2010. http://hdl.handle.net/2108/1277.
Texte intégralType I IFNs are central to a vast array of immunological functions. Their early induction in innate immune responses provides one of the most important priming mechanisms for the subsequent establishment of acquired immune responses. The outcome is either promotion or inhibition of these responses, but the conditions under which one or the other prevails remain to be defined. The main objective of the present study has been to determine the involvement of IFN on murine CD4+ CD25- Th cell activation, as well as to define the role played by this cytokine on CD4+ CD25+ Treg cell proliferation and function. Although IFN induces CD4+ CD25- Th cells co-incubated with APCs to produce large amounts of IL-2, at the same time their ability to respond to its proliferative effects is prevented. Moreover, in medium supplemented with IFN, IL-2 induced CD4+ CD25+ Treg cell proliferation is also inhibited. Notably, IFN also leads to a decrease of the CD4+ CD25+ Treg cell suppressive activity. Altogether, these findings indicate that trough a direct effect on APC activation and by affecting CD4+ CD25+ Treg cell- mediated suppression, IFN promotes and drives CD4+ CD25- Th cell activation.
SPOSITO, BENEDETTA. « Type III Interferons : Running Interference with Mucosal Repair ». Doctoral thesis, Università degli Studi di Milano-Bicocca, 2023. https://hdl.handle.net/10281/402377.
Texte intégralInterferons (IFNs) are fundamental mediators and regulators of the host immune response to viruses and other microbial agents. Type I and type III IFNs (also known as IFN-λ) are some of the first cytokines to be induced upon detection of viral infections. Signaling through their specific receptors leads to the activation of a similar signaling cascade that triggers the expression of a common set of IFN-stimulated genes (ISGs) with antiviral effector functions. The main feature that makes each of these families of IFNs unique and nonredundant is the existence of distinct receptors that differentiate them in their ability to act on virtually every cell type (type I IFNs) or exclusively on epithelial cells and a subset of immune cells (type III IFNs). Despite inducing a widely overlapping set of genes, IFN-I can mount a stronger proinflammatory response compared to IFN-III. This, coupled with the earlier induction of IFN-III upon infection, has led to the classification of IFN-III as front-line defenders of mucosal surfaces with the ability to initiate an early antiviral response with minimal tissue-damaging effects. If their response is insufficient the system shifts to the more potent and broader-acting antiviral and inflammatory IFN-I response that can cause immunopathology. In the course of my thesis, I have tested the hypothesis that also IFN-III contribute to immunopathology at barrier sites such as the respiratory and gastrointestinal epithelia during viral infections and inflammatory bowel disease/radiation-induced injury respectively. First, my colleagues and I found that in a mouse model where we mimicked the induction of antiviral responses in the respiratory tract, IFN-III produced by lung dendritic cells inhibited the proliferation of lung epithelial cells leading to an impairment in barrier restoration and an increase in susceptibility to bacterial infections. Then we measured IFN responses along the respiratory tract of COVID-19 patients. We uncovered that in the upper airways expression of IFN-I/III correlated with viral load and elderly patients, that have a higher risk of developing severe COVID-19, had a dysregulation in the IFN response. A strong expression of IFN-λ1, IFN-λ3 and ISGs characterized the upper airways of mild patients. IFN-I and IFN-λ2 together with antiproliferative and proapoptotic genes were upregulated along all the respiratory tract of severe COVID-19 patients, suggesting that they might contribute to the impairment of epithelium restitution. Finally, we demonstrated that IFN-III delayed colon and small intestine repair after dextran sulfate sodium-induced colitis and radiation-induced injury by triggering cell death of epithelial cells via the formation of a novel protein complex that includes Z-DNA binding protein (ZBP1) and gasdermin C (GSDMC). Our findings challenge the role of IFN-III as protectors of mucosal barriers as they indicate that a dysregulated IFN-III response holds the potential to contribute to immunopathology. Therefore, the clinical use of type III IFNs should be designed in such a way that their tissue-damaging functions are avoided and their beneficial effects are maximized.
Short, John A. L. « Defective interfering particles of parainfluenza virus subtype 5 and interferon induction ». Thesis, University of St Andrews, 2015. http://hdl.handle.net/10023/7036.
Texte intégralJones, Meleri. « Interfering with interferon : developing a reporter system to study the interaction between hepatitus C viral proteins and the interferon signalling pathway ». Thesis, Queen Mary, University of London, 2008. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1530.
Texte intégralO’Gorman, Maurice R. G. « Reduced in vitro IgG secretion following in vivo injection of interferon (wellferon R) in multiple sclerosis patients ». Thesis, University of British Columbia, 1985. http://hdl.handle.net/2429/24876.
Texte intégralMedicine, Faculty of
Pathology and Laboratory Medicine, Department of
Graduate
Su, Leon L. « Mechanisms of STAT activation via the interferon-[alpha]/[beta] and B cell antigen receptor and immunomodulatory role of interferons on lymphocyte development / ». Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2000. http://wwwlib.umi.com/cr/ucsd/fullcit?p9988315.
Texte intégralCastilló, Justribó Joaquín. « Indicadores precoces de respuesta al tratamiento con interferón en pacientes con esclerosis múltiple ». Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/400286.
Texte intégralIntroduction: treatment with interferon β remains the most widespread immunomodulatory therapy in the treatment of relapsing-remitting multiple sclerosis, although its efficacy is partial. In the absence of a specific biomarker of response, early identification of patients with treatment failure or a partial response is critical to defining therapeutic strategies. Objective: To study the usefulness of the Multiple Sclerosis Functional Composite to evaluate the early accumulation of disability, as well as the value of other clinical and MRI variables in the first year of treatment to predict the evolution in the following 24 months. Methods: A prospective study was designed in patients with relapsing-remitting multiple sclerosis starting treatment with interferon beta. Clinical assessment (EDSS, MSFC, relapse rate) and MRI study at baseline and after 12 months of treatment were performed. During the next 24 months the presence of disease activity (relapses or progression) was evaluated to define the long term treatment failure. Results: 165 patients, 127 in the MRI substudy, were included. The logistic regression model showed that only RM parameters (presence of more than 2 active lesions, OR 2.3, 95% CI 1.0-5.2) and composite variables (Río Score ≥2, OR 4.8 95% CI 1.6-1.4) were able to identify patients at risk of developing active disease after the first year of treatment with interferon. Conclusion: In patients with RRMS starting treatment with beta interferon, the combination of measures of disease activity and the presence of new active lesions, may have a prognostic value to identify patients who benefits from early treatment change.
Wang, Rijian. « Interferons and dermal fibrotic disorders, nitric oxide production and transforming growth factor-ß1 gene expression by normal and hypertrophic dermal fibroblasts and tissues after interferon treatment ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0008/NQ29122.pdf.
Texte intégralBusche, Andreas. « Identifizierung und Charakterisierung von Modulatoren der Interferon-[gamma]-Antwort [Interferon-Gamma-Antwort] ». [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=96971954X.
Texte intégralMigliorini, Adriana. « Role of interferon-α and interferon-β in glomerular injury and repair ». Diss., Ludwig-Maximilians-Universität München, 2014. http://nbn-resolving.de/urn:nbn:de:bvb:19-168014.
Texte intégralDominguez, Palao Francisco. « Interferon induction by paramyxoviruses : investigations into specific RNA:protein interactions ». Thesis, University of St Andrews, 2017. http://hdl.handle.net/10023/10750.
Texte intégralBazzigher, Luigi G. « Interferon-induced Mx proteins / ». Zürich, 1992. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=9650.
Texte intégralHosana, Barreto de Oliveira Francisca. « Interferon gama versus asma ». Universidade Federal de Pernambuco, 2004. https://repositorio.ufpe.br/handle/123456789/9728.
Texte intégralObjetivo: Revisar a literatura científica acerca do papel do interferon gama (IFN-y) na doença atópica, especificamente asma. Métodos: Pesquisados dados do Medline e Lilacs nos últimos 10 anos. Resultados: Vários autores discutem a importância da relação entre a secreção de IFN-y e o componente atópico per se, por outro lado é questionado se esta citocina tem relação direta com a doença asmática, independente do estado atópico. Foi verificada a existência de várias pesquisas relacionando asma e IFN-y; entretanto, os resultados destas pesquisas se apresentam controversos. Conclusão: Ainda não se chegou a uma conclusão definitiva do verdadeiro mecanismo de atuação desempenhado pelo IFN-y na doença asmática, é indiscutível a importância de novas pesquisas esclarecedoras sobre este assunto
Barbulescu, Karina. « Transkriptionelle Regulation des humanen Interferon-[gamma]-Promotors [Interferon-gamma-Promotors] in T-Lymphocyten ». [S.l.] : [s.n.], 1999. http://deposit.ddb.de/cgi-bin/dokserv?idn=959887458.
Texte intégralCarlton-Smith, Charles. « Impact of interferon β and interferon stimulated gene induction on Bunyamwera virus replication ». Thesis, University of St Andrews, 2012. http://hdl.handle.net/10023/3179.
Texte intégralNobre, Rita Luisa Valentim de Avelar. « Viral interferon antagonists and antiviral drugs / ». St Andrews, 2009. http://hdl.handle.net/10023/818.
Texte intégralBustillos, Ortiz Alcides Alberto. « Efectos de la depleción de la histona H1 en células de cáncer de mama : proliferación y respuesta a interferón ». Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/457666.
Texte intégralHistone H1 binds to linker DNA contributing to higher-order chromatin compaction. In addition, H1 seems to be actively involved in the regulation of nuclear processes such as gene expression control or DNA damage signaling. Seven linker histone H1 variants exist in human somatic cells (H1.1 to H1.5 being expressed in a replication-dependent manner, whereas H1.0 and H1X are replication-independent), with distinct prevalence depending on the cell-type analyzed and along differentiation. It is not well known whether the different variants have specific or redundant roles. We explored this by inducible shRNA- mediated knock-down of each of the H1 variants in breast cancer cells. Knock-down of each H1 variant alters expression of a different reduced subset of genes and affects cell proliferation in a different extent. Although H1.2 is the only variant essential for cells to grow in anchorage-independent conditions, being the H1 that alters the most the proliferative and metastatic properties of cancer cells. Combined depletion of H1.2 and H1.4 has a strong deleterious effect in the cancer cells examined, and induces a strong interferon (IFN) response with up-regulation of many IFN-stimulated genes (ISGs), which is not seen in individual H1 knock-downs. Although H1 participates to repress ISG promoters, its activation upon H1 KD is mainly generated by the activation of the IFN response through cytosolic nucleic acids receptors, IFN synthesis and JAK-STAT pathway activation. The IFN response may be triggered by the expression of noncoding dsRNAs generated from heterochromatic repeats or endogenous retroviruses upon H1 KD. In conclusion, redundant H1-mediated silencing of heterochromatin is important to maintain cell homeostasis and to avoid an unspecific growth-inhibiting IFN response.
Muñoz, López Laura. « Improving diagnostic strategies for latent tuberculosis infection in populations at risk for developing active disease ». Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/461911.
Texte intégralANTECEDENTES: Desde la implementación de los IGRAs (Interferon Gamma Release Assays) se ha generado poca evidencia científica fundamentada en ensayos clínicos o en el seguimiento longitudinal de cohortes. HIPÓTESIS: 1. La implementación de los IGRAs en el cribado de infección tuberculosa latente (ITL) en pacientes inmunodeprimidos puede mejorar la rentabilidad diagnóstica. 2. Los IGRAs pueden optimizar la selección de pacientes candidatos a recibir tratamiento de ITL en el estudio de contactos (EC), reduciendo su número, sin aumentar el riesgo de tuberculosis activa (TB). OBJETIVOS: 1. Demostrar la eficacia de un protocolo sistemático de prevención de TB que incluye un IGRA en los candidatos a anti-TNF. 2. Calcular los valores predictivos (VP) para el desarrollo de TB de la prueba de la tuberculina (PT) y un IGRA en pacientes candidatos a trasplante hepático (TH) o de progenitores hematopoyéticos (PH). 3. Demostrar que basar la indicación del tratamiento para ITL en el resultado de un IGRA disminuye la proporción de candidatos a tratamiento en comparación con PT, sin que por ello aumente el riesgo de TB. MÉTODOS: La tesis responde a los objetivos mediante un ensayo clínico multicéntrico y tres estudios prospectivos aprobados por el Comité de Ética del Hospital de Bellvitge, así como una revisión sistemática. RESULTADOS: 1. En candidatos a agentes anti-TNF se ha demostrado la eficacia del protocolo sistemático para la prevención de TB. El cese de PT en dos tiempos ha supuesto una disminución significativa en la proporción de diagnósticos y tratamientos de ITL sin aumentar del riesgo de TB ulterior. No es necesario repetir el cribado sistemáticamente tras un resultado negativo inicial. 2. En los candidatos a TH y de PH, el VP positivo para el desarrollo de TB del IGRA ha sido comparable a PT, siendo bajo, y por tanto no útil para predecir el desarrollo de TB. El VP negativo ha sido elevado en ambas pruebas. 3. La estrategia diagnóstica que confirma con un IGRA los resultados positivos de la PT ha demostrado ser no inferior a la estrategia basada únicamente en PT para la prevención de tuberculosis en el EC, permitiendo reducir significativamente el número de candidatos a tratamiento preventivo.
Shearer, M. A. « Monoclonal antibodies to human interferon-#alpha# applied to the study of interferon-receptor interaction ». Thesis, Open University, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.379866.
Texte intégralBurkhart, Margi Anne. « Biological activity and therapeutic applications of intracellular interferon gamma and interferon gamma mimetic peptides ». [Gainesville, Fla.] : University of Florida, 2003. http://purl.fcla.edu/fcla/etd/UFE0001180.
Texte intégralEllegast, Jana. « Interferon-Induktion durch Triphosphat-RNA ». Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-113843.
Texte intégralGhislain, Julien Johannes. « Type I interferon signal transduction ». Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0015/NQ27652.pdf.
Texte intégralEvans, T. J. « Molecular studies of interferon action ». Thesis, University of Cambridge, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.372630.
Texte intégralGage, Zoe O. « Interferon, viruses and drug discovery ». Thesis, University of St Andrews, 2017. http://hdl.handle.net/10023/10127.
Texte intégralHenfrey, Andrew Mark. « Studies on ovine interferon-gamma ». Thesis, University of Edinburgh, 1993. http://hdl.handle.net/1842/29798.
Texte intégralHerrington-Symes, A. P. « Protein-protein conjugation using interferon ». Thesis, University College London (University of London), 2015. http://discovery.ucl.ac.uk/1464509/.
Texte intégralHidmark, Åsa. « Induction of type I interferons and viral immunity / ». Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-227-9/.
Texte intégralZang, Lei. « Optimization of interferon γ gene delivery/expression system towards realization of interferon γ gene therapy ». 京都大学 (Kyoto University), 2011. http://hdl.handle.net/2433/142500.
Texte intégralTanaka, Marcia Hiromi [UNESP]. « Análise dos parâmetros clínicos periodontais e expressão genética de interferons alfa, gama e genes relacionados em indivíduos portadores de Síndrome de Down com doença periodontal ». Universidade Estadual Paulista (UNESP), 2010. http://hdl.handle.net/11449/88703.
Texte intégralA doença periodontal (DP) em indivíduos com Síndrome de Down (SD) se desenvolve com alta prevalência, precocemente, de modo rápido e generalizado em comparação com indivíduos não-sindrômicos. Foi demonstrado que portadores da SD apresentam resposta imune diminuída em relação aos cromossomicamente normais. O objetivo desta pesquisa foi investigar diferenças nos parâmetros clínicos periodontais e níveis de expressão dos genes Interferon-gama (IFNG), Interferon-gama receptor 1 (IFNGR1), Interferon-gama receptor 2 (IFNGR2), Interferon-alfa (IFNA), Interferon-alfa receptor 1 (IFNAR1), Interferon-alfa receptor 2 (IFNAR2), Janus-quinase 1 (JAK1), Transdutor de sinal e ativador da transcrição 1 (STAT1) e Fator de regulação de interferon 1 (IRF1) em indivíduos com SD que apresentam ou não DP e em indivíduos cromossomicamente normais. Fizeram parte deste estudo 80 indivíduos entre 7 e 57 anos de idade subdivididos em 4 grupos: SD com DP (A); indivíduos com SD sem DP (B); indivíduos não-sindrômicos (Controle) com DP (C) e indivíduos Controle sem DP (D). A expressão gênica foi investigada por meio de quantificação relativa utilizando a técnica da Reação em Cadeia da Polimerase (PCR) em Tempo Real. Para o índice sangramento à sondagem (SS) não houve diferença entre os grupos A e 21 C. A periodontite crônica localizada foi o tipo prevalente tanto entre indivíduos com SD como Controle. Considerando os parâmetros clínicos, não foram encontradas diferenças na periodontite crônica localizada entre os indivíduos com SD e Controle, assim como para a periodontite crônica generalizada. Com relação à análise genética, observou-se que indivíduos dos grupos com SD em relação aos grupos cromossomicamente normais (A+B-C+D) tiveram uma expressão de IFNG semelhante ao observado entre indivíduos do grupo...
Periodontal disease (PD) in individuals with Down Syndrome (DS) has an early, quickly and widespread onset and high prevalence when compared with individuals without the Syndrome. Only poor oral hygiene does not explain the severe periodontal destruction seen in DS patients. It has been shown that DS patients have a weaker immune response than people with normal number of chromosomes. The aim of this study was to investigate differences in periodontal clinical parameters and the expression levels of the genes Interferon-gamma (IFNG), Interferon-gamma receptor 1 (IFNGR1), Interferon-gamma receptor 2 (IFNGR2), interferon-alpha (IFNA), interferon-alpha receptor 1 (IFNAR1), Interferon-alpha receptor 2 (IFNAR2), Janus-kinase 1 (JAK1), Signal transducers and activators of transcription 1 (STAT1) and Interferon regulatory factor 1 (IRF1) in DS patients with and without periodontal disease in comparison with chromossomically normal individuals. A total of 80 individuals aged 7 to 57 years participated in this study and were divided into 4 groups: DS with PD (A); DS without PD (B); individuals without DS (control) with PD (C) and individuals without DS (control) and without PD (D). A quantitative RT-qPCR was used to investigate gene expression. There was no difference between groups A and C regarding the bleeding on probing 25 (BOP) index. The most prevalent type of periodontitis seen in this study was the localized chronic periodontitis, both in individuals with and without DS. Considering the clinical parameters, localized and generalized chronic periodontitis did not differ between individuals with and without DS. Regarding genetic analysis, individuals of the groups with DS in relation to the groups without DS (A+B-C+D) showed an IFNG expression similar to that seen among the individuals of groups control with PD (C-D). However, individuals... (Complete abstract click electronic access below)
Chen, Shu. « Studies on interferon (IFN) induction and isolation of IFN-inducing mutant viruses ». Thesis, University of St Andrews, 2011. http://hdl.handle.net/10023/1678.
Texte intégralRothfuchs, Antonio Carlos Gigliotti (Tony). « Interferons in immunity to chlamydia pneumoniae/ ». Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-830-0/.
Texte intégralWilson, Mark Jonathan. « Fluorescence studies of genetically engineered interferons ». Thesis, University of Kent, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.236741.
Texte intégralShabman, Reed Solomon Heise Mark T. « Alphavirus evasion of type I interferons ». Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2008. http://dc.lib.unc.edu/u?/etd,1879.
Texte intégralTitle from electronic title page (viewed Dec. 11, 2008). "... in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Microbiology and Immunology." Discipline: Microbiology and Immunology; Department/School: Medicine.
Harlin, Olof. « Die Bedeutung von Interferon alpha und Interferon gamma auf den Verlauf der Marekschen Krankheit beim Haushuhn ». Diss., lmu, 2003. http://nbn-resolving.de/urn:nbn:de:bvb:19-9116.
Texte intégralPetrenkienė, Vitalija. « Ligonių, sergančių lėtiniu hepatitu c, ligos raiškos ypatumai, gydymo interferonu a–2b ir ribavirinu efekto įvertinimas ir požymių, lemiančių gydymo rezultatus, nustatymas ». Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2005. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2005~D_20050606_220244-71931.
Texte intégralXanthoudakis, Steven. « Regulation of the human interferon-b promoter ». Thesis, McGill University, 1990. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=74353.
Texte intégralFenner, Jennifer Eve. « Regulation of Type I interferon responses ». Monash University, Centre for Functional Genomics and Human Disease, 2003. http://arrow.monash.edu.au/hdl/1959.1/9437.
Texte intégralKamphuis, Elisabeth. « Type I interferon stimulation of lymphocytes ». Giessen : VVB Laufersweiler, 2007. http://geb.uni-giessen.de/geb/volltexte/2007/4791/index.html.
Texte intégralRodrigues, Ana Mara Lopes. « Interferon, virus vaccines and antiviral drugs / ». St Andrews, 2007. http://hdl.handle.net/10023/413.
Texte intégralKamphuis, Elisabeth. « Type I interferon stimulation of lymphocytes ». Giessen VVB Laufersweiler, 2006. http://d-nb.info/988717891/34.
Texte intégralRöll, Susanne. « Identifizierung Interferon-regulierter Gene beim Haushuhn ». Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-160492.
Texte intégralType I interferons (IFNs) are an indispensable part of the innate immune response and exhibit antiviral and immunomodulatory functions. Receptor binding of IFNs induces hundreds of so called IFN-regulated genes (IRGs), which mediate the main functions of IFNs. Applying different approaches, we were able to identify a comprehensive number of IRGs in the chicken for the first time. Therefore, we performed extensive comparative database analysis and transcriptome analysis of spleen and lung tissue after intravenous injection of recombinant chicken interferon alpha (rec ChIFN-α) as well as after infection with lentogenic Newcastle Disease Virus, which is a potent inductor of Type I IFN. After IFN injection, in addition to 30% of the “common IRGs”, which exist in mammals as well as in the chicken, about 1.900 “newly identified IRGs” were found, which were regulated in the chicken, but not in the mammalian IRG databases. A closer look at these IRGs revealed that both, “common“ and “newly identified IRGs”, were involved in immunrelevant biological processes and signalling cascades, like “complement and coagulation cascades”, “Toll-like receptor signalling pathway” and ”cytokine-cytokine receptor interaction”. Moreover, by network analysis it was possible to show that “common” and “newly identified IRGs” influence each other, which confirms the hypothesis of the identification of further IRGs in the chicken. We were able to show that chicken IRGs are expressed in different expression-profiles, with many IRGs expressed only three hours after IFN injection, while others showed either a constant expression over nine hours or a more dynamic expression-profile. Furthermore, this analysis revealed a dynamic organ specific IRG expression, as some IRGs were strongly induced after three hours in the spleen and but only after nine hours in the lung. In addition we were able to identify more globally expressed IRGs, which we found in spleen and lung tissue as well, and more tissue specific IRGs, which were expressed either in spleen or in lung tissue after IFN injection and/or NDV infection. Finally, a multitude of the identified chicken IRGs could be confirmed after infection with NDV. In this experiment we were able to confirm further “common IRGs”, probably mediated due to the expression of type II and type III IFNs after NDV infection. Altogether, we were able to show, that beside of many IRGs, which exist in mammals and in chickens, there are a multitude of additional IFN induced genes in the chicken. IRGs in chickens differ depending on stimulus and analysed tissue. The obtained overview of IRGs in chickens can provide a basis for further functional characterisation. A better understanding of IFN effector mechanism can help to protect chicken and humans from dangerous pandemic infections.
Rodrigues, Ana Mara Lopes. « Interferon, virus vaccines and antiviral drugs ». Thesis, University of St Andrews, 2008. http://hdl.handle.net/10023/428.
Texte intégralGoncalves, Mario Nuno Penha. « Equine interferon-gamma and associated cytokines ». Thesis, University of Glasgow, 2000. http://theses.gla.ac.uk/1064/.
Texte intégralKong, Xiao-Fei. « Human genetic deficiencies of interferon responses ». Paris 6, 2010. http://www.theses.fr/2010PA066195.
Texte intégralNing, Shunbin. « Interferon Regulatory Factors and Autoimmune Diseases ». Digital Commons @ East Tennessee State University, 2014. https://dc.etsu.edu/etsu-works/6542.
Texte intégralStrauß, Romy [Verfasser]. « Der Einfluss von Typ-I-Interferonen auf Leukozyten-Subpopulationen im Blut : ein neuer diagnostischer Ansatz für die Verwendung der Interferon-Signatur als Biomarker beim systemischen Lupus erythematodes / Romy Strauß ». Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/1176632272/34.
Texte intégralStone, R. C., P. Du, D. Feng, K. Dhawan, Lars Rönnblom, Maija-Leena Eloranta, R. Donnelly et B. J. Barnes. « RNA-Seq for Enrichment and Analysis of IRF5 Transcript Expression in SLE ». Uppsala universitet, Reumatologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-194621.
Texte intégralKlamp, Thorsten. « Identifizierung und Charakterisierung von VLIG-1, einer neuen Interferon-induzierten GTPase ». [S.l. : s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=964404389.
Texte intégralBarchet, Winfried. « Cellular origin and molecular expression mechanisms of virus-induced type I interferon in vivo ». [S.l. : s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=964889234.
Texte intégralSchneider-Fresenius, Christian. « Entwicklung eines neuen Interferon-[beta] mit erhöhter Löslichkeit und verbesserter Bioverfügbarkeit / ». Stuttgart : Fraunhofer IRB Verl, 1999. http://www.gbv.de/dms/bs/toc/317370863.pdf.
Texte intégral